Can artificial intelligence replace human clinical trials?

  Emerging technologies such as artificial intelligence are widely concerned in the field of new drug research and development, and the concepts such as "virtual clinical trial" are also endless. On November 2nd, the world’s top scientists New Drug R & D Forum, the world’s top scientists interviewed new articles. 2013 Nobel Chemical Award Winner Arizi Wazhel focused on computer technology in new crown epidemic, the key role of the pharmaceutical industry: "Now we have a huge power to solve many problems that cannot be solved in the past." Virus as an example, Wazhel and its research teams predicted the possibility of viral mutation by calculating research by calculating research methods last June, and launched research in truly mutations.

For drug development, the computer can also be used for the combination of drugs. Under Secretary-General of the World Top Scientist Association, Yang Zhantao, a senior scientist of the world’s top scientists, mentioned artificial intelligence to develop drug development. Whether it is biological research, or pharmaceutical discovery, etc., more than just numbers, but involves real efficacy, function, effect, and drugs to patients. "Artificial intelligence is now very hot, especially in the nearly three years.

"Academician Jiang Huiliang in the Chinese Academy of Sciences, it seems that artificial intelligence is just a new technology. We still have to use it very carefully." Artificial intelligence is just an advanced technology, which can shorten the time of drug development, or help clinical The experiment collects the clinical data establishment model, and then predicts that the drug can be successful, and we can do it within 5 years. "At the same time, Jiang Huiliang also said that in actual clinical experiments, it is actually a problem, because the clinical experiment is to be carried out in the human body, rather than artificial intelligence.

  "Clinical trials should be carried out in the human body, rather than artificial intelligence." Wang Xingli, the academician Jiang Huiliang and Novarta Global Drug Development Department (China), also emphasized the subjectivity of people in clinical trials. Although the IBM laboratory has seen the frontier application of the machine study in the IBM laboratory, Wang Xingli still said that artificial intelligence is no way to replace the true body clinical trial.

  A drug does not apply to all patients, so how can patient benefit? Millions of millions of compounds may be 10,000 capable drugs, but its receptors may only apply to a small population range.

  "In the process of clinical trials, how is the drug in other large patients due to a small sample amount, and we need to be able to measure the recruitment regulations in our clinical trials. Artificial intelligence can help us at this point, which enhances the specificity of the drug and can shorten the development cycle of drugs. "Wang Xingli said. (Wang Chun).